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Next generation sequencing panels have been developed for hereditary cancer, although there is some 
debate about their cost-effectiveness compared to exome sequencing. The performance of two panels 
is compared to exome sequencing. Twenty-four patients were selected: ten with identified mutations 
(control set) and fourteen suspicious of hereditary cancer but with no mutation (discovery set). TruSight 
Cancer (94 genes) and a custom panel (122 genes) were assessed alongside exome sequencing. Eighty-
three genes were targeted by the two panels and exome sequencing. More than 99% of bases had a 
read depth of over 30x in the panels, whereas exome sequencing covered 94%. Variant calling with 
standard settings identified the 10 mutations in the control set, with the exception of MSH6 c.255dupC 
using TruSight Cancer. In the discovery set, 240 unique non-silent coding and canonic splice-site variants 
were identified in the panel genes, 7 of them putatively pathogenic (in ATM, BARD1, CHEK2, ERCC3, 
FANCL, FANCM, MSH2). The three approaches identified a similar number of variants in the shared 
genes. Exomes were more expensive than panels but provided additional data. In terms of cost and 
depth, panels are a suitable option for genetic diagnostics, although exomes also identify variants in 
non-targeted genes.
Hereditary cancer accounts for about 3% of all cancers (reviewed by Rahman)1,2 and is caused by inherited or 
de novo germline mutations in high-penetrance predisposition cancer genes. Approximately 100 cancer predispo-
sition genes have been described in the literature1,2. The presence of a mutation in one of these genes predisposes 
to certain types of tumors with varying penetrance, with a lifetime cancer risk as high as 80% in patients with 
mutations in BRCA1 or BRCA23. Genetic testing for hereditary cancers has become a paradigm of personalized or 
precision medicine in the field of cancer4–6, helping to define the risk of each family member and enabling more 
effective family surveillance, management and follow-up7. In addition, carriers can now benefit from specific 
surgical and chemotherapeutic treatment strategies8,9.
The introduction of next-generation sequencing (NGS) for routine analysis has changed the way genetic test-
ing is conceived and delivered10–12. Sanger sequencing was considered the gold standard for genetic diagnostics 
but it is a laborious and expensive procedure. Now, several dozen genes can be sequenced in a similar time 
frame and at a comparable cost to the Sanger analysis of only one large single gene13,14. As such, the inclusion of 
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high- and moderate-risk genes in a diagnostic sequencing panel may provide additional relevant clinical informa-
tion for families15–18. However, it is crucial to apply the ACCE model (Analytic validity, Clinical validity, Clinical 
utility and Associated ethical, legal and social implications) when implementing a new genetic test for diagnostic 
purposes, irrespective of the technical potential and cost advantages of the new test19.
Gene panels have been proposed as a cost-effective tool to address the underlying genetic causes of genetically 
heterogeneous disorders. Whole exome sequencing, by contrast, generates information for all known genes in the 
genome that can be used through the life of the individual and may prove more cost-effective in the long term, 
especially in the context of universal health systems20–22.
Here we present a benchmarking study in which 24 samples were NGS sequenced using three different 
approaches for library construction (two hereditary cancer panels and a whole exome panel). Our main goal is to 
assess the relative advantages and disadvantages of each methodology for diagnostic purposes.
Results
We analyzed 24 affected individuals with suspicion of hereditary cancer (Table 1, Fig. 1 and Fig. S1). Ten car-
riers of known pathogenic mutations challenging for NGS formed a control set; fourteen additional samples 
were sequenced as a discovery set. Three approaches were used, based on distinct gene libraries: (i) a Custom 
Hereditary Cancer Panel (I2HCP, ICO-IMPPC Hereditary Cancer Panel, SureSelectXT Custom 3–5.9 Mb, 
Agilent Technologies) (Santa Clara, California) (Castellanos, et al., unpublished data); (ii) the TruSight Cancer 
Sequencing Panel (TSCP, Illumina) (San Diego, California); and (iii) the SureSelect Human All Exon v5 (WES, 
Agilent) (Table 2). I2HCP is an in-house customized panel of 122 genes designed to cover the coding exons and 
intron-exon boundaries of genes associated with moderate or high risk of hereditary cancer. TSCP targets 94 
hereditary cancer genes, 83 of which are in common with the I2HCP (Table S1). The SureSelect WES kit was used 
to target all human coding exons, including those of the hereditary cancer genes covered by the panels.
Run and Mapping Quality. Quality control summary data indicated that the total number of passing filter 
reads was very similar between the two panels (approx. 7.5 million reads) and approximately 9 times higher in the 
WES (Table S2). The percentage of unique-mapping reads was higher in the WES (94.77%) than in I2HCP and 
TSCP (90.28% and 87.77%, respectively). The percentage of duplicate reads was much higher in TSCP (66.16%), 
using tagmentation and a small amount of starting DNA, than in I2HCP (2.76%) and WES (7.33%).
Target Regions, Read Depth and Coverage. The Diagnostic Region Of Interest (DxROI) for a given 
set of genes is defined here as the sum of the fragments defined by the coding bases of the coding exons plus 
20 bp (either intronic, 5′ -UTR or 3′ -UTR) surrounding each of them. The target regions were compared among 
themselves but also to the DxROI (Table S3). The reference sequence is the consensus coding sequence (CCDS)23, 
which contains protein-coding sequences with high-quality annotations. Depending on the purpose of the analy-
sis, we evaluated the set of 83 genes common to both panels and the exome (Table S1), or the set of common genes 
plus the 49 genes with CCDS ID included in either of the panels (and the exome), totaling 132 genes. Figure 2 
and Table S4 show the percentage of the 132-gene DxROI encompassed by each of the supplied target regions for 
each gene.
In hereditary cancer, where germline mutations are expected, 30 reads per base is considered the minimum 
coverage (hereafter, C30) for high-sensitivity heterozygote detection24,25. Average mean read depths of 497x, 455x 
and 129x were obtained for the 83-gene DxROI by I2HCP, TSCP and WES, respectively. More than 99% of tar-
geted bases were covered at C30 by both panels, while WES was slightly less effective (94% on average) (Fig. S2). 
The C10 base percentage is also plotted, showing the putative potential of WES if more reads per sample were 
obtained or if a Whole Exome capture kit were used that favors the medically relevant genes.
The performance of the three approaches was further compared by considering the percentage of on-target 
and off-target reads (versus own targets), the coverage uniformity of the 83-gene DxROI, and the mean read 
depth. The percentage of C30 and C10 bases versus the whole 83-gene Dx ROI or the 83-gene DxROI broken 
down into coding bases and 20 bp of intronic/UTR surrounding bases, were also considered (Fig. 3). I2HCP 
and TSCP reached > 99% C30 on their own target regions, whole DxROI and DxROI coding bases. TSCP, but 
not I2HCP, dropped slightly below 99% C30 in the intronic and UTR bases of the DxROI. WES had the highest 
on-target (75%) and the lowest off-target (8%) percentages, and although the mean coverage to which it was 
sequenced was around 3.5 times less than I2HCP and TSCP, the C30 was > 94% on the 83-gene DxROI coding 
bases and > 89% on the 20 bp surrounding the coding bases. According to diagnostic quality standards25, all 
regions not reaching the required C30 must be Sanger sequenced; WES yielded an average of 240 fragments per 
sample to be Sanger sequenced for the whole set of 83 common genes, whereas I2HCP and TSCP yielded 9 and 
19, respectively (Fig. S3). Enrichment efficiency versus GC content was also evaluated, with different patterns 
observed between capture methods (Fig. S4).
Variant Detection. An average of 111 variants per sample (range 85–119) were found in the coding regions 
plus two intronic surrounding bases (canonical splice sites) from the common genes (Fig. S5). Average concord-
ance was high: 93.8% between I2HCP and TSCP, 92.1% between I2HCP and WES, and 93.2% between TSCP 
and WES. On the whole, false positives and false negatives were fairly uniformly distributed among the three 
approaches. They were mostly linked to a small number of reads and attributable to variant calling (data not 
shown).
Variant Detection in the Control Set. Variant calling with standard settings identified the 10 pathogenic muta-
tions in the control set with the three approaches, with the exception of the MSH6 mutation c.255dupC in TSCP 
(Table 1). This mutation was probably not called due to a lower variant read ratio (0.32 in TSCP vs 0.43 in I2HCP 
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and 0.45 in WES) and the lack of forward reads at the end of that GC-rich exon. However, SAMtools called this 
variant when the p-value threshold parameter was changed from 0.5 to 0.75.
Variant Detection in the Discovery Set. A total of 240 unique non-silent coding and canonic splice-site variants 
were identified in the 132 panel genes for the 14 samples in the discovery set. Seven could be classified as highly 
probable deleterious mutations in ATM, BARD1, CHEK2, ERCC3, FANCL, FANCM and MSH2 genes (Table 1), 
corresponding to frameshift, nonsense or canonic splice site mutations. All of these mutations were confirmed by 
Sanger sequencing and detected by the three platforms, except for a nonsense mutation in BARD1 that was not 
identified by the TSCP, which does not include this gene. It should be noted that the putative pathogenic muta-
tions detected, with the exception of the ATM splice-site variant, have previously been reported as associated with 
CONTROL SET: KNOWN PATHOGENIC MUTATIONS
Family ID
Clinical 
DX Proband tumor DX age
Genes previously 
screened
Family history of 
cancer (N) Control mutation (gene) Predicted protein effect
Control-1 FAP > 100 adenomas 38 APC CRC (2), breast c.2344A > T (APC) p.(Lys782*)
Control-2 Lynch CRC 42 MMR genes CRC (3), uterine c.255dupC (MSH6) p.(Thr86Hisfs*4)
Control-3 FAP > 100 adenomas 44 APC Adenomas c.1548 + 1G > C (APC) p.?
Control-4 Lynch CRC 42 MMR genes CCR(4) c.1590_1598dupCGTGGGCTG (MLH1) p.(Gly532_Val534dup)
Control-5 AFAP 80–100 adenomas, gastric 53 MUTYH variants
Adenomas, gastric, 
lymphoma c.[1187G > A];[ 1187 G > A] (MUTYH) p.[Gly396Asp];[Gly396Asp]
Control-6 HBOCS Breast 44 BRCA1/BRCA2 Ovary, intestinal, bladder, skin, lung c.1961delA (BRCA1) p.(Lys654Serfs*47)
Control-7 HBOCS Breast 27 BRCA1/BRCA2 Breast (3), ovary c.1953_1956delGAAA (BRCA1) p.(Lys653Serfs*47)
Control-8 HBOCS Breast 38 BRCA1/BRCA2
Breast (6), gastric, 
leukemia, prostate, 
uterine
c.8946delA (BRCA2) p.(Asp2983Ilefs*5)
Control-9 HBOCS Breast 34 BRCA1/BRCA2 Ovary c.68_69delAG (BRCA1) p.(Glu23Valfs*17)
Control-10 HBOCS Breast 41 BRCA1/BRCA2
Breast (2), skin, 
melanoma, gastric, 
prostate, CRC
c.3869_3870delAA (BRCA1) p.(Lys1290Metfs*4)
DISCOVERY SET: PUTATIVE PATHOGENIC MUTATIONS IDENTIFIED IN PANEL ANALYSIS
Family ID Clinical suspicion Proband tumor DX age Genes screened
Family history of 
cancer (N) Identifed mutation (gene) Protein level
Fam-1 LFS Lung 44 TP53
MDB, GBM, CRC, 
lung, breast, GB, 
prostate, ovary
c.4776 + 2_4776 + 13delTAATAAAAATTT 
(ATM) p.(Val1538_Glu1592del)
Fam-2 HBOCS Breast (2) 40, 47 BRCA1/BRCA2 Breast (4), prostate (2) c.1921C > T (BARD1) p.(Arg641*)
Fam-3 HBOCS Ovary, CRC 22, 25 BRCA1/BRCA2, MSI/MMR genes Breast (3) c.792 + 2T > C (CHEK2) p.(Asp265Alafs*12)
Fam-4 HBOCS Breast 21 BRCA1/BRCA2, TP53 Breast c.325C > T (ERCC3) p.(Arg109*)
Fam-5 HBOCS Breast, endometrium 46, 60 BRCA1/BRCA2
Male breast, ovary, 
gastric c.1111_1114dupATTA (FANCL) p.(Thr372Asnfs*13)
Fam-6 HM Choroidal melanoma 47
BRCA1/BRCA2, 
CDKN2A
Bladder, breast, 
CRC, melanoma c.5791C > T (FANCM) p.(Arg1931*)
Fam-7 HBOCS Breast 21 BRCA1/BRCA2,TP53 STS, cervix, prostate c.2785C > T (MSH2) p.(Arg929*)
Fam-8 BC CRC 39 MMR genes Skin, gastric — —
Fam-9 BC CRC 22 MSI/MMR genes, MUTYH variants CRC, liver, polyps — —
Fam-10 LFS GIST, breast 68, 69 TP53 Breast, CRC (4), leukemia, lung — —
Fam-11 HDGC Stomach 22 CDH1 CRC (2) — —
Fam-12 HBOCS Thyroid, breast, PNET 31, 33, 34 BRCA1/BRCA2
Prostate, gastric, 
skin (2) — —
Fam-13 HBOCS Breast 46 BRCA1/BRCA2 Breast, endometrium, ADH — —
Fam-14 HBOCS Breast 19 BRCA1/BRCA2 CRC, prostate, stomach — —
Table 1.  Patient description. ADH, atypical ductal hyperplasia; AFAP, attenuated familial adenomatous 
polyposis; BC, Bethesda criteria; CRC, colorectal cancer; DX, diagnosis; FAP, familial adenomatous polyposis; 
GIST, gastrointestinal stromal tumors; GB, gallbladder; GBD; glioblastoma; HBOCS, hereditary breast and 
ovarian cancer syndrome; HM, hereditary melanoma; HDGC, hereditary diffuse gastric cancer; LFS, Li-
Fraumeni syndrome; MDB; medulloblastoma; MMR, mismatch repair; MSI, microsatellite instability; PNET, 
pancreatic neuroendocrine tumor; STS, soft tissue sarcoma.
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Figure 1. Pedigrees of the families in which a putative pathogenic mutation was identified in the panel 
genes. Filled quarters of symbols indicate patients affected by cancer (each color refers to a specific type). 
Current age, age at death and age at diagnosis (in brackets), when available, are also detailed. Putative 
pathogenic mutations are shown at the top of each pedigree; proband is marked by an arrow, carrier status was 
studied in available relatives, and those carrying/not carrying the variant are marked with +/− respectively. 
CRC, colorectal cancer; GBM; glioblastoma; Liposarc., Liposarcoma; LOH, loss of heterozygosity; MDB; 
medulloblastoma; NOS, not otherwise specified cancer; STS, soft tissue sarcoma.
www.nature.com/scientificreports/
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cancer (see references in Table S5). Further investigation of the ATM and CHEK2 variants at the canonical splice 
site by RNA analysis revealed altered splicing (Fig. S6A and B).
To support the hypothesis that these variants could be responsible for the observed phenotype, cosegregation 
studies were performed in each family, when possible, in addition to LOH of the variant in the available tumor 
samples (Fig. 1). While the clinical information for the families was good, a limited number of DNA samples 
from other affected relatives were available. Three of the identified mutations showed cosegregation with cancer 
(CHEK2, ERCC3 and FANCM). MSH2 mutation was present in all available affected relatives and also in two 
unaffected relatives. No LOH was evident in the three tumor samples available for analysis.
In the panel genes we identified 43 additional missense variants or in-frame insertions or deletions with a pop-
ulation frequency lower than 1% (Table S6). Their effect on the protein is not as straightforward as those deduced 
for truncating and canonical splice site mutations.
Finally, as expected, WES detected numerous variants with predicted high or moderate effect in several genes 
not included in the panels (Table S7). A multidisciplinary group composed of clinical geneticists, molecular biolo-
gists and NGS specialists evaluated the filtered list according to patient/family phenotype and compiled a shortlist 
of 24 putatively relevant variants in genes previously unrelated to hereditary cancer (Table S8). Fourteen of these 
variants were detected in six of the seven families that were negative for highly probable deleterious mutations in 
the panel genes. Interestingly, in two of these cases variants of genes involved in genome (POLQ) or chromatin 
(SETD4) stability were detected, so these findings also open new avenues for investigating cancer susceptibility.
Comparison of approaches and Turn-Around Times. A study was performed of the consumables, com-
puting, data storage and time requirements for the overall sequencing and analysis process to establish a rough 
comparison of the sequencing options and turn-around time for the three approaches (Table 2). The overall price 
of consumables for DNA capture and library preparation was similar for the three libraries (around €150–200/
sample). Library preparation time is similar in I2HCP and WES (4–5 days) and slightly shorter in TSCP (3 days). 
The price of sequencing and run-time per sample depend on the specific sequencing options (Table 2). Crucially, 
WES requires around 10 times more sequences. In terms of data storage, panel results generate an average of 2 GB 
Enrichment approach I2HCP TSCP WES
Library design
Kit, supplier
Custom 
SureSelect, 
Agilent
TruSight Cancer, 
Illumina
All Exon v5, 
Agilent
Target region 400 Kb 255 Kb 50,400 Kb
Target genes 122 94 ≈ 21,500
Target SNPs 47 identification, 43 risk 284 risk All coding SNPs
Technical details
Input DNA 3 μ g DNA 50 ng DNA 3 μ g DNA
Bait length 120-mer RNA 80-mer DNA 120-mer RNA
Fragmentation Covaris DNA shearing Nextera tagmentation
Covaris DNA 
shearing
Capture In solution hybridization In solution hybridization
In solution 
hybridization
Prepared at CNAG ICO CNAG
Library prep. 
time 4–5 days 3 days 4–5 days
Run
Platform Hiseq 2000, Illumina Hiseq 2000, Illumina
Hiseq 2000, 
Illumina
Kit TruSeq SBS v3: 200 cycle TruSeq SBS v3: 200 cycle
TruSeq SBS v3: 
200 cycle
Throughput 24 patients/lane, 1.5 Gb/patient
24 patients/lane, 1.5 Gb/
patient
2.6 patients/lane, 
13.6 Gb/patient
Run time 11 day 11 day 11 day
Computing per sample
CPU time 50 h 44 h 93 h
Storage 2.2 GB 1.7 GB 20.5 GB
Other sequencing options. 
HiSeq2500 rapid run
Kit
HiSeq rapid SBS 
kit v2, 200 cycle, 
60 Gb
HiSeq rapid SBS kit v2, 
200 cycle, 60 Gb
HiSeq rapid SBS 
kit v2, 200 cycle, 
60 Gb
Throughput 40 patients/flow cell 40 patients/flow cell
4.3 patients/flow 
cell
Run time 27 h 27 h 27 h
Other sequencing options. MiSeq
Kit
MiSeq Reagent 
kit v3: 600 cycle, 
15 Gb
MiSeq Reagent kit v3: 
600 cycle, 15 Gb
Not feasible with 
MiSeqThroughput 10 patients/flow cell 10 patients/flow cell
Run time 39 h 39 h
Table 2.  Study design.
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Figure 2. Theoretical and observed coverage of the 132-gene Diagnostic Region of Interest (DxROI): base 
percentage of the DxROI of the 132 genes targeted by any of the panels and the exome, covered by the three 
different sequencing strategies. (a) Theoretical coverage. Percentage coverage of the DxROI for each gene is 
obtained by comparing the designed target regions, as provided by each manufacturer (TSCP and WES) or 
aimed for in the I2HCP design. (b) Observed coverage. Percentage of DxROI bases of each gene effectively 
covered at a read depth ≥ 30x (C30) by each strategy; the median of the 24 samples is shown.
www.nature.com/scientificreports/
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Figure 3. Comparison of main coverage metrics. Average of all samples and 95% confidence interval 
are shown in each bar plot for the three approaches. (a) Performance metrics: passing filter (PF) reads; 
percentage of on-target reads, defined as any read overlapping at least one base the target region defined by the 
corresponding approach, versus total PF reads; percentage of off-target reads, defined as those within regions 
more than ± 500-bp outside the designed own target regions; and uniformity of the coverage of the 83-gene 
DxROI (Diagnostic Region of Interest), calculated as the fraction of CCDS coding exons plus 20 bp boundaries 
reaching a mean read depth within ± 70% of the mean read depth over all coding exons plus 20 bp boundaries. 
(b) Mean read depth, percentage of bases with read depth at least 30x and 10x versus: own target regions, the 
whole 83-gene DxROI, or considering the coding bases and their 20-bp boundaries separately.
www.nature.com/scientificreports/
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of data per sample, whereas WES produces about 20 GB per sample. Although computing (CPU) time to obtain 
alignments and variant lists is approximately double for WES (Table 2), parallelization means that results can be 
obtained in only a few hours (wall clock time) in both cases.
Discussion
This study reports a comprehensive comparison of ad hoc panels for hereditary cancer syndromes and WES in the 
clinical diagnostic setting, where high standards of quality and accuracy are required, and laboratories are under 
pressure to deliver short turn-around times for multiple tests.
From the clinical perspective, I2HCP and WES proved robust in the detection of bona fide previously iden-
tified pathogenic point mutations. The commercial TSCP panel missed one mutation at the end of a GC rich 
exon. Since the design and protocols of standard commercial kits are fixed, there is not much that can be done to 
improve coverage of certain regions from the user perspective. Therefore, regions of interest with bad quality or 
poor coverage need to be analyzed with alternative techniques. Notably, all platforms identified putative patho-
genic mutations in half of the discovery families tested, either in high-risk genes (such as MSH2), in moderate-risk 
genes (CHEK2, ATM, BARD1) or in genes related to hereditary cancer susceptibility without a well-known asso-
ciated risk (FANCM, FANCL, ERCC3). Co-segregation (CHEK2, ERCC3 and FANCM) and functional effect at 
RNA level (ATM, CHEK2) have been demonstrated in some genealogies, although large case-control sequencing 
studies and larger family-based studies will be needed to better define the risks before most of these genes can be 
routinely used in the clinical setting. WES identified 24 potentially damaging mutations in the 14 probands. The 
value of these findings is difficult to estimate, but they can put and end to the diagnostic odyssey and can also shed 
light on the compound deleterious effects of multiple mutations.
High performance standards are essential in the clinical diagnostic setting12,21,25–28. The critical difference 
between panel sequencing and WES is coverage. Under standard conditions, WES aims for a mean read depth 
of around 100× 29,30, while panel sequencing generally targets a range of 200–1000× 14,27,31. Assuming a “standard 
run” for both approaches, our study clearly demonstrates that the number of target region bases not reaching 
C30 is much higher in WES than in panel sequencing. As such, the number of Sanger sequences required for 
diagnostic-quality results increases for WES, thereby increasing the overall cost of the test. It is obviously cheaper 
to sequence a panel than an exome due to the much smaller capture region, but this gap is narrowing as, for exam-
ple, the sequencing costs of an exome are 50% lower with a HiSeq 4000 compared to a HiSeq 2000. Moreover, the 
development of comprehensive panels targeting most clinically relevant genes (around four thousand), such as 
TruSight One (Illumina), or exome kits offering better coverage for disease-associated targets (such as, Agilent’s 
SureSelect Clinical Research Exome and SureSelect Focused Exome or Roche’s SeqCap EZ MedExome) would 
be more cost-effective than standard WES. However, it must be taken into consideration that our I2HCP panel 
required a cost for development and validation that has not been included here and that TSCP and WES are both 
labeled for research use only, meaning that proper validation by the user’s laboratory is required before they can 
be applied in a diagnostic setting.
On the other hand, panel data results are easier to interpret than full WES results, since fewer genes are con-
sidered and we know more about their mutational spectrum and clinical relevance in cancer. However, in favor 
of WES, a two-step approach could be used in bioinformatic analysis by first identifying putative pathogenic 
variants in a list of candidate genes before investigating the sequence of the other exome genes obtained in the 
same experiment.
In this study we have focused on the comparison of single nucleotide variant (SNV) and insertion/deletion 
detection, since these approaches are highly sensitive and specific to detect this kind of mutations. However, 
other mutations such as copy number variations (CNV) are difficult to detect with these methods. Therefore, our 
diagnostics workflow includes MLPA (Multiplex Ligation-dependent Probe Amplification) of the main genes of 
clinical interest. Alternative techniques such as aCGH (array comparative genomic hybridization), with higher 
throughput but lower resolution, are other viable options. In the future, additional tests might not be necessary 
if new targeting approaches, like the Agilent OneSeq 1 Mb CNV Backbone + Custom Panel, or bioinformatic 
methods overcome the current limitations.
Turn-around time is important in the clinical setting25,32. For several cancer types, results must be obtained 
quickly because chemotherapy (i.e. BRCA status and PARP inhibitors) or surgery decisions depend on mutational 
status8. Shorter turn-around time is achieved with panel results, as the analysis itself is quicker and the list of vari-
ants to analyze/validate is much shorter. However, a partial analysis of the exome could also be performed, which 
would put it on a par. Sequencer type and run times are also important considerations: panels can be sequenced 
in a benchtop NGS sequencer such as MiSeq (Illumina), whereas WES needs a higher sequencing throughput 
as provided by a HiSeq 2000 or a newer sequencer, which is not always feasible for clinical laboratories (Table 2). 
However, sequencing cost per GB is higher for MiSeq than for HiSeq.
The clinical utility of a given test is critical when choosing a methodology. Ethical issues related to puta-
tive incidental findings should be considered and discussed with the patient before ordering a genetic test10,33,34. 
Although considerable advances have been made over the last decade in our understanding of the molecular basis 
of several cancer syndromes, the translation of this knowledge into clinical surveillance and patient management 
remains limited. The risks associated with mutations in several cancer genes are still unknown, making it difficult 
to apply the genetic information obtained in daily patient care. As WES reveals mutations in uncharted genes, a 
degree of uncertainty remains that must be addressed.
There are benefits of analyzing target genes using ad hoc panels, as they focus on the regions of greatest interest 
and return clinical-grade results at a good cost. However, as our knowledge grows frequent updates are necessary. 
WES, by contrast, identifies the variants of interest, although some regions do not reach clinical sensitivity; informa-
tion about other clinically relevant observations is immediately available and hardly any updates will be necessary.
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Methods
Patients and DNA Extraction. A total of 24 affected individuals were selected from unrelated families 
with family history of cancer attending our Cancer Genetic Counseling Units. Genetic testing had been indi-
cated because of: 1) early-onset cancer; and/or 2) multiple tumors in a patient, and/or 3) familial aggregation of 
cancer suggestive of a dominant pattern of inheritance (Table 1, Fig. 1 and Fig. S1). Ten cases were positive for 
technically challenging mutations (control set). The remaining 14 were negative in the routine analysis of one or 
a few candidate genes by conventional Sanger sequencing (discovery set). Informed consent was obtained from 
all subjects and the study received the approval of the Ethics Committee of the Institut d’Investigació Biomedica 
de Bellvitge (IDIBELL) (PR073/12), which fulfills the International ethical guidelines for biomedical research 
involving human subjects. The methods were carried out in accordance with the approved guidelines. Genomic 
DNA from peripheral blood was used for NGS.
Next-generation Sequencing: Library Preparation. Library preparation was conducted according 
to the manufacturers’ instructions (TSCP at the Catalan Institute of Oncology (ICO), WES and I2HCP at the 
National Center for Genomic Analysis (CNAG)).
SureSelect Custom Panel (I2HCP). A total of 122 genes were targeted for a final capture size of 400 kb 
(SureSelectXT Custom 3–5.9 Mb, Agilent) (Castellanos, et al., unpublished data), according to Agilent’s 
SureSelect protocol for Illumina paired-end sequencing. Briefly, 3.0 μ g of genomic DNA was sheared on a Covaris 
E210 instrument (Covaris, Woburn, Massachusetts). The fragment size (150–300 bp) and the quantity were con-
firmed with an Agilent 2100 Bioanalyzer 7500 chip. Fragmented DNA was end-repaired, adenylated and ligated 
to Agilent indexing-specific paired-end adaptors. The DNA with adaptor-modified ends was PCR amplified 
(6 cycles, Herculase II fusion DNA polymerase, Agilent) with SureSelect Primer and SureSelect Pre-capture 
Reverse PCR Primer, quality controlled on the DNA 7500 assay for the library size range of 250 to 450 bp and 
hybridized for 24 hours at 65 °C (Applied Biosystems 2720 Thermal Cycler). The hybridization mix was washed in 
the presence of magnetic beads (Dynabeads MyOne Streptavidin T1, Life Technologies, Carlsbad, California) and 
the eluate was PCR amplified (16 cycles) in order to add the index tags using SureSelectXT Indexes for Illumina. 
The final library size and concentration were determined on an Agilent 2100 Bioanalyzer 7500 chip.
TruSight Cancer Panel (TSCP) (Illumina). This enrichment system targeted 94 genes associated with heredi-
tary cancer syndromes. Libraries were generated using TruSight Rapid Capture along with the TruSight Cancer 
Sequencing Panel (Illumina), according to the manufacturer’s sample preparation protocol. Briefly, 50 ng of each 
DNA sample were enzymatically fragmented and adapter sequences were added to the ends. The fragmented 
DNA was purified and barcodes and common adapters required for cluster generation and sequencing were 
PCR-added. After cleanup, 500 ng of each 12 DNA libraries were pooled. Then the libraries were hybridized twice 
to specific capture probes; the unhybridized material was washed away and the captured fragments were ampli-
fied using PCR followed by purification. The enriched libraries were quantified using a Qubit 2.0 Fluorometer and 
their quality was evaluated using a Bioanalyzer 2100 and the High Sensitivity DNA Kit (Agilent Technologies). 
Libraries were diluted and pooled to obtain the final sequencing equimolar pool.
Whole Exome Sequencing (WES). Library preparation for the capture of selected DNA regions (Agilent Human 
All Exon 50 Mb v5, Agilent Technologies) was performed with the same protocol as for I2HCP (see above).
Next-generation Sequencing: Run. Each WES library was sequenced at CNAG on an Illumina HiSeq 
2000 system in a fraction of a sequencing lane, following the manufacturer’s protocol, with a paired end run of 
2 × 101 bp, with at least 98% of the target region covered at C10, following CNAG standards for exome sequenc-
ing. For TCSP and I2HCP panels, 24 samples were sequenced on one lane of an Illumina HiSeq 2000 with 
2 × 101 bp paired-end mode. In all cases, image analysis, base calling and quality scoring were processed using 
the manufacturer’s Real-Time Analysis software (RTA 1.13.48, HCS 1.5.15.1), followed by generation of FASTQ 
sequence files in CASAVA.
Next-generation Sequencing: Data Analysis and Variant Calling and Prioritization. The same 
algorithms and settings were used for all three approaches. Reads were hard-trimmed from the end up to the first 
base, with a quality of at least 10. Reads at least 40 nt in length were mapped to the human genome build hg19 
[hs37d5] (http://www.1000genomes.org/category/reference) using GEM toolkit35 allowing up to 4 mismatches. 
Alignment (.bam) files containing only properly paired, unique-mapping reads were processed using Picard tools 
release 1.110 (http://picard.sourceforge.net) to add read groups and to remove duplicates. The Genome Analysis 
Tool Kit (GATK) version 3.1 (https://www.broadinstitute.org/gatk/)36 was used for local realignment. Processed 
.bam files were submitted to variant calling for single nucleotide variants and small insertions and deletions 
using SAMtools version 0.1.19 (http://samtools.sourceforge.net/)37. Functional annotations were added using 
snpEff (http://snpeff.sourceforge.net/)38 with the GRCh37.75 database. Human dbSNP version 137, population 
frequencies from 1000 Genomes and the Exome Variant Server, as well as conservation and deleteriousness pre-
dictions from dbNSFP (http://sites.google.com/site/jpopgen/dbNSFP)39, were annotated using snpSift (http://
snpeff.sourceforge.net/SnpSift.html)40.
Given the number of variants identified in WES, and in order to prioritize them, variants were filtered accord-
ing to several stringent criteria (Table S8). Briefly, we discarded variants i) with an allelic population frequency 
≥1% according to the 1000 Genomes Project and Exome Variant Server data annotated with dbNSFP v2.5 
(http://varianttools.sourceforge.net/Annotation/DbNSFP); ii) observed more than once in our set of 24 
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samples; iii) with low sequencing quality, or iv) with an allele ratio < 0.25. Of the variants that met these crite-
ria, we selected those most likely to be pathogenic according to the SnpEff v.3.6 annotation tool (http://snpeff.
sourceforge.net), which classified them as HIGH impact (frameshift, nonsense, STOP lost/gain, exon/chromo-
some deletion, canonic splice-site), and directly related to cancer according to the VarElect prioritization tool 
(http://varelect.genecards.org).
Variant validations, cosegregation and LOH studies. Putative pathogenic variants confirmation, 
cosegregation studies and  loss of heterezygosity analysis  were performed by Sanger sequencing using the prim-
ers listed in Table S9.
Cell cultures for RNA analysis. Human lymphocytes from fresh and frozen samples were maintained in 
RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemented with with PHA (Phytohemagglutinin) (10 μ g/ml 
RPMI medium), 10% fetal calf serum and 1% penicillin-streptomycin (Sigma, Saint Quentin Favallier, France) 
in a 5% CO2 incubator at 37 °C. Human lymphocytes were cultured in the absence or presence of puromycin 
(Sigma Aldrich, St. Louis). Puromycin, a translational inhibitor that prevents potential degradation of unstable 
transcripts by the Nonsense-Mediated mRNA Decay (NMD) mechanism, was added to a final concentration of 
100 μ g/ml of culture for 4–6 hours prior to RNA isolation.
RNA isolation and RT-PCR. Total RNA was isolated using TRIzol reagent (Invitrogen), according to the 
manufacturer’s instructions. Five hundred ng of total RNA from each sample were reverse-transcribed (RT) in 
a 20 μ l reaction, which also contained 1x reaction buffer, 0.5 mM dNTPs, 1x DTT, 2 ng random hexamers and 
200 units of Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). The reaction conditions were 
5 min at 65 °C, 10 min at 25 °C, 50 min at 42 °C, and 10 min at 70 °C. The subsequent PCR was performed using 
2 μ l of the cDNA mixture with specific primers targeting the region of interest (Table S9). RT-PCR products were 
separated by electrophoresis on a 1.5–3.0% agarose gel containing ethidium bromide and visualized by exposure 
to UV light and sequenced on an ABI 3730xl sequencer (Applied Biosystems, Foster City, CA) using Big Dye 
Terminator v3.1 cycle sequencing reaction kit (Applied Biosystems).
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